Eamonn Quigley, DDW 2021: Biotherapeutic Blautia Hydrogentrophica in IBS
It was a pleasure to speak with Prof. Eamonn Quigley (Houston Methodist Hospital, Houston, TX, USA) about the phase 2 study of the single-strain live biotherapeutic, Blautia hydrogentrophica (Blautix), currently under investigation in irritable bowel syndrome (IBS).
His abstract entitled ‘A Phase 2 Study of Live Biotherapeutic Blautix in Irritable Bowel Syndrome (IBS) Patients with subtypes IBS-C and IBS-D’ (Sa607) was presented at DDW, 21-23 May 2021.
- What are the limitations of current treatments for IBS? (0:28)
- What is Blautix and what is the rationale for its use in the treatment of adults with IBS-C and IBS-D? (01:29)
- Could you tell us a little about the aims and design of the Phase II study you presented? (2:37)
- What are the efficacy and safety findings by region and what was the reason for the differences? (03:46)
Disclosures: Prof Eamonn Quigley has received research support, and acted as a consultant to 4D Pharma.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of DDW 2021 (Virtual).
Share this Video
Related Videos In Digestive Disorders
UEG Digestive Health Month: Matthias Löhr, May 2023
Digestive Health Month took place over May 2023 to raise awareness of digestive diseases and cancers, which often remain overlooked in terms of policy, funding and research in Europe. We were delighted to talk with UEG’s Vice President Prof. Matthias Löhr (Karolinska Institutet, Stockholm, Sweden) around the public health and economic burden of digestive diseases, […]
Stefan Schreiber, ECCO’23: Corticosteroid-free remission with etrasimod in ulcerative colitis – analysis of the ELEVATE UC 52 study
The ELEVATE UC 52 study (NCT03945188) investigated the efficacy and safety of etrasimod in patients with moderately to severely active ulcerative colitis, a recent analysis of the study was presented at ECCO’23 looking at corticosteroid (CS)-free remission as a clinical endpoint. In this touchIMMUNOLOGY interview, we spoke with Dr. Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, […]
Stefan Schreiber, ECCO’23: Current treatment paradigm for ulcerative colitis and corticosteroid-free remission as a treatment goal
The current treatment paradigm for ulcerative colitis (UC) includes amino salicylic acid as a first line treatment followed by corticosteroids, targeted treatment and rectal topical therapy; however, with corticosteroids (CS) impacting long-term health, CS-free remission has become a long-term goal in treatment. Etrasimod is an S1P receptor modulator, recently investigated for the treatment of UC […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!